New Sequencing Methods Reveal Off-Target Effects of CRISPR/Cas9 | GenomeWeb

NEW YORK (GenomeWeb) – Two recently published sequencing methods demonstrate the ability to systematically reveal unintended consequences of CRISPR/Cas9 activity in the genome.

The methods could provide researchers with an accurate and unbiased tool to gauge the specificity of the gene editing technology as it moves closer toward clinical therapeutic use, according to experts.

The ability of the Cas9 nuclease to create a double-stranded break is the crux of CRISPR, but scientists have been reporting off-target effects and have to design their experiments to account for it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Mar
16
Sponsored by
Agilent Technologies

This online seminar will discuss how improvements on the front end and back end of the sequencing workflow can lead to better RNA-seq results.

Mar
28

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.